{
  "id": 5038063,
  "title": "Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations",
  "url": "https://urgent.news/2026/09/02/alteogen-signs-deal-with-novartis-worth-up-to-3-2-bil-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T07:22:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times",
    "url": "https://www.koreatimes.co.kr/business/companies/20260902/alteogen-signs-deal-with-novartis-worth-up-to-32-bil-for-subcutaneous-formulations"
  },
  "original_language": "en",
  "account": "Korean biotech firm Alteogen Inc. has inked a licensing and option deal with Novartis AG, valued at up to $3.2 billion, to develop and market subcutaneous (SC) drug formulations. The agreement grants Novartis exclusive rights to create and sell these SC formulations, using Alteogen's ALT-B4 technology, across various products. In addition to the potential $3.2 billion payout upon meeting all milestones, Alteogen will also earn royalties on net sales following commercialization. ALT-B4, a recombinant human hyaluronidase developed via Alteogen's Hybrozyme platform, facilitates the conversion of intravenous (IV) biologic drugs into SC formulations. This marks the fourth ALT-B4 licensing agreement Alteogen has struck with a global pharmaceutical company this year. ALT-B4 works by temporarily breaking down hyaluronic acid, a crucial component of the extracellular matrix, to aid drug delivery.",
  "summary": "Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won ($3.2 billion) to develop and commercialize subcutaneous (SC) formulations using its ALT-B4 technology. Under the agreement, the Swiss pharmaceutical company will have exclusive rights, through multiple options, to develop and commercialize SC…",
  "key_points": [
    "Alteogen signs $3.2B deal with Novartis for subcutaneous drug formulations.",
    "Novartis gets exclusive rights to use Alteogen's ALT-B4 technology.",
    "ALT-B4 converts IV drugs to SC formulations using Hybrozyme platform."
  ],
  "editors_take": "This deal cements Alteogen's position as a key player in the biotech industry, with its ALT-B4 technology attracting significant attention from major pharmaceutical companies, and sets it up for substantial future earnings.",
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Yonhap News",
        "title": "Alteogen signs deal with Novartis worth up to 4.4 tln won for subcutaneous formulations",
        "url": "https://urgent.news/2026/09/02/alteogen-signs-deal-with-novartis-worth-up-to-4-4-tln-won-for",
        "published": "2026-09-02T06:49:23.000Z"
      },
      {
        "outlet": "The Korea Times",
        "title": "Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations",
        "url": "https://urgent.news/2026/09/02/alteogen-signs-deal-with-novartis-worth-up-to-3-2-bil-for-5039394",
        "published": "2026-09-02T07:32:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}